Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 28 January 2013 | By Alexander Gaffney, RAC,
French regulatory authorities, already reeling from two major scandals involving regulated healthcare products, are now facing yet a third involving an acne and contraceptive drug known as Diane-35.
A report authored by French regulator ANSM and obtained by French newspaper Le Figaro describes serious adverse events suffered by approximately 125 women who took the drug, which is manufactured by Bayer.
The currently unpublished report-set to be released this week-details the deaths from thrombosis of at least four women who took the drug, reports Reuters. An additional three deaths were possibly linked to use of the drug, but less clearly. It remains unclear if those deaths were caused by the drug, or merely associated with it.
Diane-35, generically known as cyproterone acetate, regulates hormones, and is primarily used to treat acne. However, in many countries it is either indicated for use or used off-label as an oral contraceptive-part of the so-called third and fourth generation of contraceptives.
In response to the concerns raised in the report, ANSM has reportedly asked the European Medicines Agency (EMA) to review third- and fourth-generation combined oral contraceptives to determine if there is a need to restrict their use to women who are otherwise unable to take other, earlier-generation combined oral contraceptives.
"France has made this request amid recent initiatives to reduce the use of third- and fourth-generation combined oral contraceptives by French women in favor of using second-generation oral contraceptives," EMA wrote in an online post announcing the review.
EMA's announcement noted the already-established risk of patients developing blood clots, but said its Pharmacovigilance Risk Assessment Committee (PRAC) would review the contraceptives to "give its opinion on whether the currently available product information provides the best information possible for patients and doctors to take appropriate healthcare decisions."
Regulators said this is the "first time" that a member state has requested a review and recommendation regarding a medicine under the new pharmacovigilance legislation.
The potential scandal comes in the wake of two other major scandals that occurred between 2011 and 2012 when ANSM's predecessor, Afsapps, was rocked by allegations that it had kept the diabetes drug Mediator on the marketed for years longer than it should have to benefit French drug manufacturer Servier. Then, in 2012, regulators were again rocked by findings that medical device manufacturer Poly Implant Prothese, a breast implant manufacturer, had for years sold a defective implant product made with industrial-rather than medical-grade silicone.
French legislators would eventually reconstitute Afssaps as ANSM in the hopes of giving the regulator a new start and freshened image, as well as new authorities with which to regulate products in postmarket settings.
Regulatory Focus newsletters
All the biggest regulatory news and happenings.